-+ 0.00%
-+ 0.00%
-+ 0.00%

Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026

Benzinga·10/22/2026 11:36:37
Listen to the news

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present three key poster presentations at the upcoming 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in Boston. The presentations focus on Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) for the treatment of early AD, including preliminary baseline characteristics of study participants, study participant and partner experience, and treatment expectations and motivations. The conference will be held November 16-19, 2026, both in-person and online.